RxDoctor Payments Data

Christine Myers

Nurse Practitioner · Camp Hill, PANPI 1578581872

Payments from drug & device makers

$4,557in general payments, 2019–2025

Across 19 payments — averaging $239.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cequr Corporation$4K
  • Abbott$186
  • Sanofi-aventis U.S. LLC$121
  • Lilly USA, LLC$57
  • Novo Nordisk$34
  • Biotronik Inc.$30
  • plus $30 from 2 others

What the payments were for

  • Speaking & faculty fees$3,87885%
  • Food & beverage$66815%
  • Education$120%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,557 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$31,846
Medicare patients
132
Services billed
371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide200$256,961
JardianceEmpagliflozin194$201,307
OzempicSemaglutide144$196,631
MounjaroTirzepatide129$170,689
Tresiba Flextouch U-100Insulin Degludec91$78,425
RybelsusSemaglutide39$73,601
FarxigaDapagliflozin Propanediol53$47,382
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog44$42,907
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog37$38,018
Novolog FlexpenInsulin Aspart125$37,387
Humulin R U-500 KwikpenInsulin Regular, Human24$34,136
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/729$33,236
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog40$28,199
Tresiba Flextouch U-200Insulin Degludec13$28,014
Humalog Kwikpen U-100Insulin Lispro72$28,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog$57$432,282340 claims
Novo NordiskOzempic, Rybelsus, Novolog, Xultophy 100-3.6$34$298,504233 claims
Sanofi-aventis U.S. LLCAdmelog, Lantus$121$12,88028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Camp Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →